PT. PathGen Diagnostik Teknologi currently working closely with Indonesian Institute of Sciences/ Lembaga Ilmu Pengetahuan Indonesia (LIPI) for COVID-19 detection. LIPI and PathGen are joining the effort to support Indonesia in COVID-19 diagnostic test by assisting local hospitals in Jakarta and surrounding areas. Diagnostic test will soon be performed in Biosafety Level 3 Facility located in LIPI Cibinong Science Center, West Java, Indonesia. This effort is done due to the fact that Indonesia is one of the countries with very limited capacity for the detection of SARS-CoV-2. As per early April, Indonesia only performed 300 test/million population compared with neighboring countries Malaysia, Singapore, and Thailand is 5000, 4000, and 2500 test/million population respectively (Source: https://www.worldometers.info).
COVID-19 affects people globally, including Indonesia. Immediate action is required to tackle this before our health system overwhelmed and takes large toll. Thus in this dire times, PathGen are trying our best to support the effort against COVID-19 in Indonesia through our expertise in the field of genetics and molecular diagnostics.
With the increasing number of different types of PCR reagents coming from overseas, prior method optimisation and validation are required to select most accurate and suitable kit to be used in available facilities through out the country. In coordination with several LIPI researchers, PathGen research associates, Gilang and Satrio, supervised by Mr. Asep M Ridwanuloh, are assisting in method validation for real-time PCR (Polymerase Chain Reaction) detection of SARS-CoV-2 virus. In the following weeks, PathGen team will also directly involved in the diagnosis of patients’ clinical specimen.